Video

Dr. Lee on the Results of the ENTRATA Trial in Advanced RCC

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the phase II ENTRATA trial in advanced renal cell carcinoma (RCC).

Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the phase II ENTRATA trial in advanced renal cell carcinoma (RCC).

Data presented at the 2019 ESMO Congress indicated that the addition of the glutaminase inhibitor telaglenastat to everolimus extended progression-free survival versus everolimus alone in patients with heavily pretreated advanced RCC, meeting the prespecified endpoint of the ENTRATA trial. In the trial, the median progression-free survival was 3.8 months in the combination arm versus 1.9 months in the monotherapy arm (HR, 0.64; 95% CI, 0.34-1.20; one-sided P = .079).

These data demonstrate proof-of-concept for telaglenastat and support the use of glutaminase inhibition as a potential treatment strategy in advanced RCC, says Lee. The role of glutaminase inhibition is being further evaluated in the ongoing phase II CANTATA study, in which patients with advanced or metastatic RCC are being randomized to either telaglenastat in combination with cabozantinib (Cabometyx) or placebo plus cabozantinib.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.